Ventricular assist devices for bridge to myocardial repair.

[1]  L. Cooper,et al.  A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy , 2007, Journal of clinical apheresis.

[2]  Y. Nosé.  Therapeutic artificial organs: future perspectives. , 1985, Artificial Organs.

[3]  R. Hetzer,et al.  Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. , 2000, Circulation.

[4]  Y. Nosé.  Blood purification procedures and their related short- and long-term effect on patients. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[5]  G. Wallukat,et al.  Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy , 2002, Circulation.

[6]  Yukihiko Nosé,et al.  Therapeutic left ventricular assist device and apheresis on dilated cardiomyopathy. , 2004, Artificial organs.

[7]  N. Koga.  The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[8]  G. Baumann,et al.  Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. , 2005, American heart journal.

[9]  Johannes Müller,et al.  Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy , 2004, The European Journal of Health Economics, formerly: HEPAC.

[10]  Magdi H Yacoub,et al.  Left ventricular assist device and drug therapy for the reversal of heart failure. , 2006, The New England journal of medicine.

[11]  Yukihiko Nosé,et al.  Artificial organs for bridge to therapy. , 2004, Artificial organs.

[12]  M Pohl,et al.  Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. , 2000, Journal of the American College of Cardiology.

[13]  G. Baumann,et al.  Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. , 2004, International journal of cardiology.

[14]  W O Richter,et al.  RheoSorb: a specific adsorber for fibrinogen elimination in clinical situations with impaired rheology. , 2002, Artificial organs.

[15]  L. Cooper,et al.  Treatment of chronic dilated cardiomyopathy with immunoadsorption using the staphylococcal A‐Agarose column: A comparison of immunoglobulin reduction using two different techniques , 2007, Journal of clinical apheresis.

[16]  J. Willerson,et al.  Adult stem cell therapy in perspective. , 2003, Circulation.

[17]  Y. Izumi,et al.  Effects of cellular cardiomyoplasty on ventricular remodeling assessed by Doppler echocardiography and topographic immunohistochemistry. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[18]  S. Felix,et al.  Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. , 2006, American heart journal.